Sorafenib + temozolomide

Sorafenib + temozolomide is a combination therapy of two oral small molecule drugs used primarily in oncology clinical trials. Sorafenib is a multikinase inhibitor that targets several kinases involved in tumor cell proliferation and angiogenesis, including Raf serine/threonine kinases (Raf-1, B-Raf), vascular endothelial growth factor receptor 1 (VEGFR-1), vascular endothelial growth factor receptor 2 (VEGFR-2), vascular endothelial growth factor receptor 3 (VEGFR-3), platelet-derived growth factor receptor beta (PDGFR-β), KIT, FLT3, and RET. Temozolomide is an alkylating agent that induces DNA damage by methylation at the O6 and N7 positions of guanine. The combination has been investigated for synergistic antitumor effects in high-grade glioma/glioblastoma and advanced melanoma. Mechanistically, the combination inhibits tumor growth through dual mechanisms: sorafenib blocks cell signaling pathways critical for proliferation and angiogenesis while temozolomide induces cytotoxic DNA damage; together they also inhibit JAK2/STAT3 signaling and promote autophagy via oxidative stress-mediated pathways[1][2][3][4][5][6].

Brand names

Nexavar

Other names

Low-dose temozolomide plus sorafenibChemo-switch regimen